Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you suffered losses in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a ...

LOS ANGELES, Oct. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Unicycive Therapeutics, Inc., (“Unicycive” or the "Company") (NASDAQ: UNCY) investors off a class action on behalf of investors that bought securities between March 29, 2024 and June 27, 2025, inclusive (the “Class Period”). Unicycive investors have until October 14, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you suffered losses in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 05, 2025 (GLOBE NEWSWIRE) -- Faruqi ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional information] , /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading ...

Accessibility StatementSkip Navigation Join the case to recover your losses. LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. ("Unicycive" or "the Company") (NASDAQ: UNCY ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of UNCY during the class period listed are encourage ...

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Unicycive To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Unicycive between March 29, 2024 and June 27, 2025and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional inform ...

诉讼核心信息 - Schall Law Firm提醒投资者针对Unicycive Therapeutics, Inc (NASDAQ: UNCY) 的集体诉讼已提起 该诉讼指控公司违反了1934年证券交易法的§§10(b)和20(a)条款以及美国证券交易委员会制定的10b-5规则 [1] - 诉讼涉及的集体诉讼期定义为2024年3月29日至2025年6月27日期间购买公司证券的投资者 这些投资者被鼓励在2025年10月14日前联系该律师事务所 [2] 指控内容 - 指控称公司在市场上发布了虚假和误导性声明 夸大了其满足FDA生产合规要求的能力 [4] - 公司被指控夸大了其用于治疗透析慢性肾病患者的血磷过高药物OLC获得FDA批准的可能性 [4] - 基于这些事实 公司在整个集体诉讼期间的公开声明是虚假的且具有重大误导性 当市场了解到Unicycive的真相后 投资者遭受了损失 [4] 律师事务所信息 - Schall Law Firm是一家全国性的股东权利诉讼公司 代表全球投资者 专门从事证券集体诉讼和股东权利诉讼 [5]

公司事件 - 律师事务所Faruqi & Faruqi正在调查Unicycive Therapeutics公司 并提醒投资者在2025年10月14日前申请成为集体诉讼的首席原告[4] - 诉讼指控公司及高管违反联邦证券法 通过做出虚假和/或误导性陈述及/或未能披露相关信息[6] - 指控具体内容包括公司夸大其满足FDA生产合规要求的能力 以及夸大OLC新药申请的监管前景[6] 监管进展 - 2025年6月10日公司披露FDA在其第三方制造供应商处发现cGMP合规缺陷 导致无法进行标签讨论[7] - 此消息导致公司股价下跌3.68美元 跌幅达40.89% 收盘价为5.32美元[7] - 2025年6月30日FDA针对OLC新药申请发出完整回复函 再次提及先前发现的cGMP缺陷[8] - 此消息导致公司股价进一步下跌2.03美元 跌幅达29.85% 收盘价为4.77美元[8] 投资者影响 - 诉讼涵盖期间为2024年3月29日至2025年6月27日 针对损失超过50,000美元的投资者[1] - 法院指定的首席原告将是集体成员中财务利益最大且具有代表性的投资者[9] - 投资者可选择通过律师申请成为首席原告 或保持缺席集体成员身份[9]

公司监管合规事件 - 公司被指控在2024年3月29日至2025年6月27日期间违反联邦证券法 发布虚假和/或误导性声明 未能披露其满足FDA生产合规要求的能力被夸大[6] - 公司OLC新药申请(NDA)的监管前景被夸大 导致公司公开声明在相关时间段存在重大虚假和误导性内容[6] FDA审查与公司回应 - 2025年6月10日公司披露FDA在第三方制造供应商处发现cGMP合规缺陷 这些缺陷出现在公司合同开发和制造组织(CDMO)的分包商处[7] - 由于发现的缺陷 FDA禁止公司与机构进行任何标签讨论[7] - 2025年6月30日FDA针对OLC NDA发出完整回应函 再次引用先前在CDMO分包商处发现的cGMP合规问题[8] 股价市场反应 - 2025年6月10日公司股价下跌3.68美元/股 跌幅40.89% 收盘价报5.32美元/股[7] - 2025年6月30日公司股价进一步下跌2.03美元/股 跌幅29.85% 收盘价报4.77美元/股[8] 法律程序进展 - 联邦证券集体诉讼已于2025年10月14日设定申请担任首席原告的最后期限[4] - 法院将任命在救济寻求中拥有最大财务利益的投资者作为首席原告 该投资者需能代表推定类别成员指导并监督诉讼[9]